Harms AS[au] - Search Results

Year	Number of Results
2008	1
2009	1
2010	1
2011	2
2012	2
2013	2
2014	2
2015	1
2016	4
2017	3
2018	3
2019	1
2020	4
2021	5
2022	4
2023	5

1

Periphery and brain, innate and adaptive immunity in Parkinson's disease.

Harms AS, Ferreira SA, Romero-Ramos M. Harms AS, et al. Acta Neuropathol. 2021 Apr;141(4):527-545. doi: 10.1007/s00401-021-02268-5. Epub 2021 Feb 8. Acta Neuropathol. 2021. PMID: 33555429 Free PMC article. Review.

2

CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.

Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. Williams GP, et al. Among authors: harms as. Brain. 2021 Aug 17;144(7):2047-2059. doi: 10.1093/brain/awab103. Brain. 2021. PMID: 33704423 Free PMC article.

3

Inflammation in Experimental Models of α-Synucleinopathies.

Harms AS, Kordower JH, Sette A, Lindestam Arlehamn CS, Sulzer D, Mach RH. Harms AS, et al. Mov Disord. 2021 Jan;36(1):37-49. doi: 10.1002/mds.28264. Epub 2020 Oct 3. Mov Disord. 2021. PMID: 33009855 Free PMC article. Review.

4

'Seeding' the idea of early diagnostics in synucleinopathies.

Gallups NJ, Harms AS. Gallups NJ, et al. Among authors: harms as. Brain. 2022 Apr 18;145(2):418-419. doi: 10.1093/brain/awac062. Brain. 2022. PMID: 35259250 No abstract available.

5

Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders.

Standaert DG, Harms AS, Childers GM, Webster JM. Standaert DG, et al. Among authors: harms as. Handb Clin Neurol. 2023;193:95-106. doi: 10.1016/B978-0-323-85555-6.00011-4. Handb Clin Neurol. 2023. PMID: 36803825 Review.

6

Innate and adaptive immune responses in Parkinson's disease.

Schonhoff AM, Williams GP, Wallen ZD, Standaert DG, Harms AS. Schonhoff AM, et al. Among authors: harms as. Prog Brain Res. 2020;252:169-216. doi: 10.1016/bs.pbr.2019.10.006. Epub 2019 Dec 5. Prog Brain Res. 2020. PMID: 32247364 Free PMC article. Review.

7

Postoperative drug-induced priapism.

Corten BJGA, Aarts F, Harms AS, Vogelaar J. Corten BJGA, et al. Among authors: harms as. BMJ Case Rep. 2017 May 31;2017:bcr2016218060. doi: 10.1136/bcr-2016-218060. BMJ Case Rep. 2017. PMID: 28566410 Free PMC article.

8

Glial GLP1R: A novel neuroprotector?

Schonhoff AM, Harms AS. Schonhoff AM, et al. Among authors: harms as. Mov Disord. 2018 Dec;33(12):1877. doi: 10.1002/mds.27547. Epub 2018 Nov 14. Mov Disord. 2018. PMID: 30427545 No abstract available.

9

Editorial: Glial-targeted therapeutics for CNS disease: getting there from here.

Tansey MG, Harms AS. Tansey MG, et al. Among authors: harms as. Front Cell Neurosci. 2023 Jul 3;17:1231648. doi: 10.3389/fncel.2023.1231648. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37465212 Free PMC article. No abstract available.

10

Central and peripheral innate and adaptive immunity in Parkinson's disease.

Harms AS, Yang YT, Tansey MG. Harms AS, et al. Sci Transl Med. 2023 Nov 8;15(721):eadk3225. doi: 10.1126/scitranslmed.adk3225. Epub 2023 Nov 8. Sci Transl Med. 2023. PMID: 37939158 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

35 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year